PURPOSE OF REVIEW: Focal laser ablation (FLA) is an emerging treatment paradigm for prostate cancer that aims to successfully eradicate disease while also reducing the risk of side-effects compared with whole-gland therapies. RECENT FINDINGS: Preclinical and phase I clinical trials for low-risk prostate cancer have shown that FLA produces accurate, predictable, and reproducible ablation zones with negligible injury to the surrounding tissues. Because FLA is magnetic resonance compatible, the procedure can be monitored with real-time feedback to optimize targeted treatment of cancerous foci and minimize quality-of-life side-effects. The oncologic efficacy of MRI-guided FLA is currently being evaluated in ongoing phase II clinical trials. SUMMARY: FLA is a well tolerated and feasible therapy for low-risk prostate cancer, and the oncologic efficacy of this treatment modality is currently under investigation in phase II clinical trials at several institutions.
PURPOSE OF REVIEW: Focal laser ablation (FLA) is an emerging treatment paradigm for prostate cancer that aims to successfully eradicate disease while also reducing the risk of side-effects compared with whole-gland therapies. RECENT FINDINGS: Preclinical and phase I clinical trials for low-risk prostate cancer have shown that FLA produces accurate, predictable, and reproducible ablation zones with negligible injury to the surrounding tissues. Because FLA is magnetic resonance compatible, the procedure can be monitored with real-time feedback to optimize targeted treatment of cancerous foci and minimize quality-of-life side-effects. The oncologic efficacy of MRI-guided FLA is currently being evaluated in ongoing phase II clinical trials. SUMMARY:FLA is a well tolerated and feasible therapy for low-risk prostate cancer, and the oncologic efficacy of this treatment modality is currently under investigation in phase II clinical trials at several institutions.
Authors: Uri Lindner; Nathan Lawrentschuk; Robert A Weersink; Sean R H Davidson; Orit Raz; Eugen Hlasny; Deanna L Langer; Mark R Gertner; Theodorus Van der Kwast; Masoom A Haider; John Trachtenberg Journal: Eur Urol Date: 2010-03-12 Impact factor: 20.096
Authors: H Ballentine Carter; Peter C Albertsen; Michael J Barry; Ruth Etzioni; Stephen J Freedland; Kirsten Lynn Greene; Lars Holmberg; Philip Kantoff; Badrinath R Konety; Mohammad Hassan Murad; David F Penson; Anthony L Zietman Journal: J Urol Date: 2013-05-06 Impact factor: 7.450
Authors: Jonas Hugosson; Sigrid Carlsson; Gunnar Aus; Svante Bergdahl; Ali Khatami; Pär Lodding; Carl-Gustaf Pihl; Johan Stranne; Erik Holmberg; Hans Lilja Journal: Lancet Oncol Date: 2010-07-02 Impact factor: 41.316
Authors: Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Alvaro Páez; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Sigrid Carlsson; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Paula M Kujala; Bert G Blijenberg; Ulf-Hakan Stenman; Andreas Huber; Kimmo Taari; Matti Hakama; Sue M Moss; Harry J de Koning; Anssi Auvinen Journal: N Engl J Med Date: 2012-03-15 Impact factor: 91.245
Authors: Aytekin Oto; Ila Sethi; Gregory Karczmar; Roger McNichols; Marko K Ivancevic; Walter M Stadler; Sydeaka Watson; Scott Eggener Journal: Radiology Date: 2013-02-25 Impact factor: 11.105
Authors: Monica Morrow; Reshma Jagsi; Amy K Alderman; Jennifer J Griggs; Sarah T Hawley; Ann S Hamilton; John J Graff; Steven J Katz Journal: JAMA Date: 2009-10-14 Impact factor: 56.272
Authors: U Lindner; R A Weersink; M A Haider; M R Gertner; S R H Davidson; M Atri; B C Wilson; A Fenster; J Trachtenberg Journal: J Urol Date: 2009-08-14 Impact factor: 7.450
Authors: Alex Z Wang; Amir H Lebastchi; Luke P O'Connor; Michael Ahdoot; Sherif Mehralivand; Nitin Yerram; Samir S Taneja; Arvin K George; Rafael Sanchez-Salas; John F Ward; Pilar Laguna; Jean de la Rosette; Peter A Pinto Journal: World J Urol Date: 2021-01-02 Impact factor: 4.226
Authors: Dominic J Gavin; Bruce D Wilkie; Jia Tay; Benjamin P T Loveday; Timothy Furlong; Benjamin N J Thomson Journal: ANZ J Surg Date: 2020-08-17 Impact factor: 2.025